US Pharma MarketingDrug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation. The headline fight in FY2025 pharma happened at the very top of the leaderboard, where Keytruda held the No. 1 brand slot even as Lilly’s tirzepatide and Novo’s semaglutide passed it at the molecule level. We covered that reshuffle in a separate analysis . Look past Keytruda, Mounjaro and Ozempic and the FY2025 table shows an industry where scaled specialty franchises are still compounding rather than plateauing. Skyrizi, Rinvoq, Dupixent, Darzalex, Tremfya and Kisqali all posted meaningful gains, and Immunologicals remain one of…
The headline fight in FY2025 pharma happened at the very top of the leaderboard, where Keytruda held the No. 1 brand slot even as Lilly’s tirzepatide and Novo’s semaglutide passed it at the molecule level. We covered that reshuffle in a separate analysis. Look past Keytruda, Mounjaro and Ozempic and the FY2025 table shows an…
The post Pharma 50: The 50 best-selling drugs of FY2025 appeared first on Drug Discovery and Development.
Source: Drug Discovery & Development